ABCB1 variants and sex affect serotonin transporter occupancy in the brain

[1]  H. Ruhé,et al.  The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review , 2021, Molecular Psychiatry.

[2]  A. Schene,et al.  Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder , 2020, Psychiatric genetics.

[3]  G. M. Godbersen,et al.  Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR , 2019, Front. Mol. Neurosci..

[4]  A. Serretti,et al.  Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice , 2019, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[5]  G. M. Godbersen,et al.  Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging , 2019, European Neuropsychopharmacology.

[6]  W. Wadsak,et al.  A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. , 2018, Nuclear medicine and biology.

[7]  K Domschke,et al.  Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 , 2017, Pharmacopsychiatry.

[8]  Lucas Rischka,et al.  Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion , 2017, NeuroImage.

[9]  K. Treviño,et al.  Antidepressant Medication Prescribing Practices for Treatment of Major Depressive Disorder. , 2017, Psychiatric Services.

[10]  Manfred Uhr,et al.  ABCB1 genotyping in the treatment of depression. , 2016, Pharmacogenomics.

[11]  A. Serretti,et al.  Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study , 2016, European Neuropsychopharmacology.

[12]  F. Holsboer,et al.  Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. , 2016, Journal of psychiatric research.

[13]  D. Rujescu,et al.  Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET , 2015, Human brain mapping.

[14]  N. Freemantle,et al.  Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. , 2015, The American journal of psychiatry.

[15]  P. Chen,et al.  Association between ABCB1 Polymorphisms and Antidepressant Treatment Response in Taiwanese Major Depressive Patients , 2015, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[16]  L. Lazzeroni,et al.  ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. , 2015, The American journal of psychiatry.

[17]  L. Lázaro,et al.  Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients , 2014, The Pharmacogenomics Journal.

[18]  Pia Baldinger,et al.  Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET , 2014, NeuroImage.

[19]  D. Rujescu,et al.  Impact of COMT genotype on serotonin-1A receptor binding investigated with PET , 2013, Brain Structure and Function.

[20]  Xin Li,et al.  ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. , 2013, Pharmacogenomics.

[21]  J. Ahlner,et al.  Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment , 2013, European Neuropsychopharmacology.

[22]  A. Hofman,et al.  Association Between Genetic Variation in the ABCB1 Gene and Switching, Discontinuation, and Dosage of Antidepressant Therapy: Results From the Rotterdam Study , 2013, Journal of clinical psychopharmacology.

[23]  J. A. Boer,et al.  ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder , 2012, The Pharmacogenomics Journal.

[24]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders , 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[25]  D. Marazziti,et al.  Pharmacokinetics and pharmacodinamics of psychotropic drugs: effect of sex , 2013, CNS Spectrums.

[26]  Kelan Thomas,et al.  P-glycoprotein (PGP) Polymorphisms and Sexual Dysfunction in Female Patients With Depression and SSRI-Associated Sexual Side Effects , 2013, Journal of sex & marital therapy.

[27]  P. Riederer,et al.  Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions , 2013, Journal of Neural Transmission.

[28]  M. Berk,et al.  ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression , 2012, Translational Psychiatry.

[29]  R. Boellaard,et al.  P-Glycoprotein Function at the Blood–Brain Barrier: Effects of Age and Gender , 2012, Molecular Imaging and Biology.

[30]  C. Bundgaard,et al.  Species Comparison of In Vivo P-Glycoprotein-Mediated Brain Efflux Using mdr1a-Deficient Rats and Mice , 2012, Drug Metabolism and Disposition.

[31]  C. Bundgaard,et al.  Associating in vitro target binding and in vivo CNS occupancy of serotonin reuptake inhibitors in rats: The role of free drug concentrations , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  Christer Halldin,et al.  Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder , 2012, The international journal of neuropsychopharmacology.

[33]  B. Griffin,et al.  Interactions between antidepressants and P‐glycoprotein at the blood–brain barrier: clinical significance of in vitro and in vivo findings , 2012, British journal of pharmacology.

[34]  J. Kehr,et al.  Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study , 2011, Journal of psychopharmacology.

[35]  A. Malafosse,et al.  Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. , 2011, Pharmacogenomics.

[36]  N. Kokras,et al.  Sex differences in pharmacokinetics of antidepressants , 2011, Expert opinion on drug metabolism & toxicology.

[37]  Y. Chiu,et al.  ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment , 2010, Pharmacogenetics and genomics.

[38]  L. Lazzeroni,et al.  ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression , 2010, Pharmacogenetics and genomics.

[39]  P. Hardy,et al.  Antidepressants and ABCB1 Gene C3435T Functional Polymorphism: A Naturalistic Study , 2010, Neuropsychobiology.

[40]  N. Božina,et al.  The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone , 2010, European Journal of Clinical Pharmacology.

[41]  R. Perlis,et al.  Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated Patients , 2010, Biological Psychiatry.

[42]  P. Muglia,et al.  Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. , 2010, The American journal of psychiatry.

[43]  B. Pollock,et al.  Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: an updated review. , 2009, Gender medicine.

[44]  S. Apparsundaram,et al.  Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in Rats , 2009, Drug Metabolism and Disposition.

[45]  O. Spigset,et al.  Serum Concentrations of Antidepressant Drugs in a Naturalistic Setting: Compilation Based on a Large Therapeutic Drug Monitoring Database , 2009, Therapeutic drug monitoring.

[46]  C. Eap,et al.  Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. , 2008, Pharmacological research.

[47]  N. Božina,et al.  MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[48]  F. Holsboer.  How can we realize the promise of personalized antidepressant medicines? , 2008, Nature Reviews Neuroscience.

[49]  C. Eap,et al.  CYP2D6 and ABCB1 Genetic Variability: Influence on Paroxetine Plasma Level and Therapeutic Response , 2008, Therapeutic drug monitoring.

[50]  G. Jenkins,et al.  Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample , 2008, PloS one.

[51]  K. Linnet,et al.  A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs , 2008, European Neuropsychopharmacology.

[52]  A. Serretti,et al.  ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[53]  Christer Halldin,et al.  Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET , 2008, NeuroImage.

[54]  F. Holsboer,et al.  Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression , 2008, Neuron.

[55]  J. Booij,et al.  Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  S. Duan,et al.  Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. , 2006, Pharmacogenomics.

[57]  F. Larsen,et al.  The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects , 2005, Journal of clinical pharmacology.

[58]  A H Thomson,et al.  Cost-Effectiveness of Therapeutic Drug Monitoring: A Systematic Review , 2005, Therapeutic drug monitoring.

[59]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[60]  C. Baumgartner,et al.  Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy , 2004, Neurology.

[61]  F. Holsboer,et al.  Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption , 2003, Biological Psychiatry.

[62]  M. Grauer,et al.  abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. , 2003, Journal of psychiatric research.

[63]  Maurizio Fava,et al.  Diagnosis and definition of treatment-resistant depression , 2003, Biological Psychiatry.

[64]  W. Haefeli,et al.  Inhibition of P-Glycoprotein by Newer Antidepressants , 2003, Journal of Pharmacology and Experimental Therapeutics.

[65]  Stephen A. Williams,et al.  Changes in Human In vivo Serotonin and Dopamine Transporter Availabilities during Chronic Antidepressant Administration , 2003, Neuropsychopharmacology.

[66]  P. Joyce,et al.  A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression , 2002, The Pharmacogenomics Journal.

[67]  Alan A. Wilson,et al.  Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[68]  M Fujita,et al.  Sex differences in [123I]β‐CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers , 2001, Synapse.

[69]  P. Renshaw,et al.  Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. , 2000, The American journal of psychiatry.

[70]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  A. Schinkel,et al.  P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[72]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.